https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/best-biotech-stocks-to-add-to-your-watchlist-september-10th-d8ab2eff220ca406 2026-09-10T16:04:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/xocova-offers-new-post-exposure-covid-19-prevention-option-for-adolescents-180741a4ba145920 2026-09-10T15:57:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/hsil-extends-biotech-index-to-malaysia-s-warrant-market-7d7be353577cf20e 2026-09-10T15:26:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/kala-shankle-on-what-comes-next-for-national-licensure-74efa622bca91473 2026-09-10T15:23:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/minister-agrees-to-review-pharmacy-amendments-to-health-bill-46a2c884d11eb4a4 2026-09-10T15:19:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-changes-the-how-not-the-what-ccddb8218dba7492 2026-09-10T15:15:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-at-citi-summit-cash-rich-biotech-leans-on-three-pillars-60ac4a42be1a796f 2026-09-10T14:55:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-trial-of-experimental-dm1-treatment-fails-to-hit-main-goal-47fea7492ee4aa03 2026-09-10T14:55:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-fda-pauses-new-enrollment-in-biohaven-s-epilepsy-drug-trials-2130c9870ed50f98 2026-09-10T14:45:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-limited-reports-earnings-results-for-the-second-quarter-end-fe9932e3452b9015 2026-09-10T14:37:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifth-circuit-judges-press-louisiana-on-standing-as-mifepristone-stays-available-7803e41623ffd424 2026-09-10T14:30:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962ce 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253def 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05c 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06e 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843d 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86 2026-09-10T14:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-past-endpoints-11-winners-fared-as-the-biotech-industry-rebounded-b43f9ce8182c04f8 2026-09-10T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-security-market-competitive-landscape-analyzed-across-leading-glo-ae872b3a3ec772bd 2026-09-10T14:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/greater-philadelphia-regional-life-sciences-roundup-september-10-2026-a692fddd69a19c9d 2026-09-10T14:28:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/glenmark-and-south-piedmont-open-2-7-million-pharmaceutical-training-facility-0b4260fbc2643d82 2026-09-10T14:18:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-cracks-down-on-unsafe-food-banned-products-17cbcad470576ff1 2026-09-10T14:14:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/stalled-generous-globe-and-guard-initiatives-create-international-pricing-uncert-01e4dff956d74dff 2026-09-10T14:13:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-health-equity-champions-can-learn-from-pharmaceutical-sales-9d780c13222a1501 2026-09-10T13:59:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-places-partial-hold-on-biohaven-s-ion-channel-drug-f305595bf9c3c703 2026-09-10T13:58:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbc 2026-09-10T13:52:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-raids-11-food-units-in-thane-seizes-materials-worth-rs-20-48-lak-9f75fd7cc7276ce7 2026-09-10T13:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-nets-1-1b-in-long-running-fund-aimed-at-small-midsize-biot-6cbd4c5bcf9742eb 2026-09-10T13:44:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/adarx-pharmaceuticals-seeks-ipo-on-strong-collaboration-deal-with-abbvie-pending-5dba419255f531e9 2026-09-10T13:41:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-expands-bayer-lung-cancer-drug-approval-71178ea7131e5c0a 2026-09-10T13:39:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-b0c70810964568e8 2026-09-10T13:33:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-biologics-signs-usd-262-million-manufacturing-agreement-with-european-ph-d2defa9f379bb988 2026-09-10T13:32:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/imunon-enters-cooperative-research-and-development-4ff7c827c11dfc18 2026-09-10T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-at-wells-fargo-conference-growth-outlook-lifts-7e95f35a8d9d2806 2026-09-10T13:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scynexis-appoints-sanjay-subramanian-cfo-as-biotech-advances-rare-disease-pipeli-7ffff17544555b0f 2026-09-10T13:28:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abb 2026-09-10T13:27:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrna-cancer-vaccines-biggest-barriers-to-market-5a32cb9618b921d8 2026-09-10T13:26:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-s-long-serving-r-d-chief-andy-plump-to-retire-in-wake-of-pipeline-success-59af07bbf36e86fb 2026-09-10T13:25:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-public-fund-lifting-it-to-2-8b-e142f1ed47f39964 2026-09-10T13:25:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/hplc-degasser-upgraded-biotech-fluidics-launches-the-degasi-ng-platform-28b7579689b125bf 2026-09-10T13:23:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-releases-q2-2026-financial-results-8819331f3d074a9a 2026-09-10T13:22:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/update-starton-therapeutics-to-present-at-medinvest-biotech-pharma-conference-d467c5ff3d6873eb 2026-09-10T13:19:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-pre-market-movers-tnon-aeon-surge-coo-cdt-slide-a99c6eadfee151c8 2026-09-10T13:17:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-seeks-fda-meeting-to-plan-phase-3-trial-for-parkinson-s-drug-candidate-4c45ecc8dc428588 2026-09-10T13:16:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/25f1670-gloflon-i-v-catheter-with-injection-valves-wings-20g-1-1-x-33mm-666903112fb8586e 2026-09-10T13:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/cannara-biotech-secures-58m-credit-facility-with-bmo-and-td-5c15a8e996887473 2026-09-10T13:07:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/latest-figures-highlight-ongoing-meningitis-b-risk-for-students-d7de382570d1ec44 2026-09-10T13:06:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-q2-revenue-falls-9-3-to-rmb134-7m-cafe7127e11ce51e 2026-09-10T13:04:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090 2026-09-10T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69 2026-09-10T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/no-treatment-is-approved-for-menstrual-migraine-abbvie-s-drug-cut-migraine-days-6a69b46a841b8f13 2026-09-10T12:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-me-aa42924a07011e55 2026-09-10T12:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-pulse-dhl-s-new-singapore-hub-and-pharma-rethinks-go-to-market-6f1e39d1bd379b78 2026-09-10T12:53:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/geovax-provides-nasdaq-listing-update-and-reaffirms-focus-on-advancing-strategic-e2e455613a5a2210 2026-09-10T12:37:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/unlocking-cell-surface-protein-research-with-site-specific-labelling-4b2c27c5d4f0630d 2026-09-10T12:34:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncolytics-biotech-reports-preclinical-pelareorep-activity-maintained-with-ras-i-acb108f11ddc1118 2026-09-10T12:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/daesang-expands-into-pharmaceutical-grade-amino-acids-7525345f8975eea5 2026-09-10T12:15:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-experimental-cancer-treatment-combination-reduced-tumor-growth-in-early-tests-915d2ac78c60b6c6 2026-09-10T12:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-investigational-cell-therapy-for-alzheimer-s-and-parkinson-s-will-be-presente-9bd92b46dfeadd3f 2026-09-10T12:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-look-at-cleanassure-by-freudenberg-medical-1781dee31e7a4af8 2026-09-10T12:00:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/imn-screws-system-advanced-locking-screw-ec5f499d9db6b051 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-on-five-year-remission-with-a-myeloma-treatment-will-be-presented-in-scotla-a31339569a772091 2026-09-10T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-biohaven-pharmaceutical-stock-sliding-today-d8352213f625eea5 2026-09-10T11:46:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/data-aggregation-drives-ai-s-impact-on-clinical-supply-chains-c09c4abbac6eea8f 2026-09-10T11:35:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapi-8e9e18b565ad084e 2026-09-10T11:34:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/3145507-hippokratis-10x20-ply-ref-1020121301-070cc64470b4812d 2026-09-10T11:33:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-hair-brand-vegamour-snapped-up-by-kvd-beauty-owner-belle-brands-9e5b5f7223daebe3 2026-09-10T11:30:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-s-q2-revenue-falls-net-loss-widens-on-central-laboratory-we-3a2bfe5a57b7c6c6 2026-09-10T11:29:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/burning-rock-biotech-reports-second-quarter-2026-financial-results-and-business-3604b6a838f831f6 2026-09-10T11:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-appl-173e26866817c76e 2026-09-10T11:13:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-simulation-help-foundation-trainee-pharmacists-prepare-for-prescribing-754b389753a9f647 2026-09-10T11:12:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/migraine-and-acne-included-in-new-prescribing-pharmacy-first-pathways-3ea2469614a56a9c 2026-09-10T11:12:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/uzbekistan-pharmaceutical-output-reaches-uzs-3-5-trillion-in-seven-months-e698870d82152c1b 2026-09-10T11:10:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-1-2-clinical-trial-of-opgx-best1-shows-positive-results-for-inherited-reti-693efb757e3769e0 2026-09-10T11:09:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/podcast-key-readouts-from-esc-and-ers-37928ee094726d75 2026-09-10T11:00:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-suicide-risk-research-will-join-five-posters-on-a-treatment-e30968146e5d4bba 2026-09-10T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sk-biopharm-s-in-licensed-epilepsy-drug-opcalim-hits-partial-fda-clinical-hold-58e7c243c85a1a2c 2026-09-10T10:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-appoints-permanent-fda-cber-cder-heads-40d9e998d4d06de3 2026-09-10T10:52:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/spain-pushes-for-access-toolbox-in-eu-biotech-rules-1688a317e36915f9 2026-09-10T10:48:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/join-the-danish-medicines-agency-s-atmp-open-house-c8681c32f51f75b3 2026-09-10T10:39:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout-e0aa083eeef3c734 2026-09-10T10:36:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/roivant-is-one-of-the-savviest-dealmakers-in-biotech-it-also-has-a-secret-weapon-c406bfe29c9a43b3 2026-09-10T10:36:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/squarepoint-ops-llc-sells-106-171-shares-of-ultragenyx-pharmaceutical-inc-rare-aaef604b00280d03 2026-09-10T10:16:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-prices-4-9-billion-senior-notes-offering-and-anno-b1e8ff5e4e7ab9df 2026-09-10T10:11:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/power-optimization-solution-ends-costly-grid-related-shutdowns-at-major-pharmace-895389c9339efb13 2026-09-10T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/active-pharmaceutical-ingredients-market-demand-insights-ee7be79d74ee8b32 2026-09-10T09:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-assessment-27-countries-how-eu-joint-reviews-work-afdce1a4bab2fa1a 2026-09-10T09:44:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-the-er-is-not-an-option-milestone-s-cmo-on-bringing-afib-rate-control-home-e2e99f9bbe1ee809 2026-09-10T09:36:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-takeda-announces-planned-retirement-of-president-of-cc51e8d4bc8214ff 2026-09-10T09:34:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-announces-planned-retirement-of-president-of-research-deve-57aa87713cda8888 2026-09-10T09:34:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/systech-launches-traceiq-0628e750134c6813 2026-09-10T09:33:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-ud-s-star-campus-is-helping-companies-foster-innovation-in-biotech-bfd0e22feb57c6cb 2026-09-10T09:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-growth-trust-stands-out-in-a-stronger-biotechnology-sector-0c5fc1ee6f1de77b 2026-09-10T09:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/me-therapeutics-stock-faces-downside-pressure-as-biotech-risk-and-preclinical-un-1ec2178796d0ffa0 2026-09-10T09:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocorrx-inc-appoints-former-acting-white-house-drug-policy-director-richard-j-b-f65963320838259a 2026-09-10T09:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yourgene-insight-dpyd-assay-gets-ivdr-accreditation-0f45b3e7e51c89f2 2026-09-10T09:10:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/mog-fda-35ed387f5c4715ce 2026-09-10T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-announces-u-s-fda-grants-priority-review-for-enspryng-for-myelin-oligodend-399e802924ad2be2 2026-09-10T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/samsung-biologics-signs-350-8-billion-long-term-cmo-deal-with-european-pharmaceu-f69633ea36eaf3ad 2026-09-10T08:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-launch-degasi-ng-platform-03359e408ef2f244 2026-09-10T08:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/dong-a-socio-holdings-to-rename-itself-dong-a-pharmaceutical-after-otc-merger-811dc3505dca9b48 2026-09-10T08:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-upgrades-its-degasi-inline-degasser-range-2e8eb202eff2dd75 2026-09-10T08:35:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-evidence-matters-seema-meloni-on-making-data-meaningful-ec1cdcab294170da 2026-09-10T08:33:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323 2026-09-10T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884 2026-09-10T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007 2026-09-10T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60 2026-09-10T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20ce 2026-09-10T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/venture-investor-danish-biotech-innovation-has-caught-up-with-sweden-3b75feb145abd779 2026-09-10T08:20:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-packaging-market-c2e9bc2e819d9a7b 2026-09-10T08:16:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-22eadb56d9fb8544 2026-09-10T08:16:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/gov-healey-eyes-changes-to-life-sciences-programs-as-early-stage-biotechs-strugg-17782bbe9a7546e8 2026-09-10T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-e6c409ade4de9fa6 2026-09-10T07:51:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-6-september-2026-10a6be24e936e540 2026-09-10T07:34:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-820ecbff0a7a966c 2026-09-10T07:29:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-335870a76488db42 2026-09-10T07:28:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-ae1ac0815b2896b3 2026-09-10T07:27:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-bfc75e0710215140 2026-09-10T07:26:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-permanent-leaders-of-fda-drug-and-vaccine-centers-setting-the-directio-a1123af1f2b72c44 2026-09-10T07:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approve-0b079b33cbbfd08d 2026-09-10T07:00:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-begins-phase-iii-trial-of-ai-discovered-drug-rentosertib-for-i-dadb1e5c66814ac8 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/psi-cro-to-present-agile-models-for-emerging-biotech-at-oct-new-england-833dc325de531768 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-enrolls-first-patient-in-phase-3-trial-of-istaroxime-for-2b1bb847cd17d245 2026-09-10T06:46:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/genencell-scandal-revives-korea-s-kosdaq-bio-rout-as-trust-erodes-and-risk-mount-fb54093710b5acb6 2026-09-10T06:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chinese-salmon-by-products-targeted-in-12-8m-biotech-deal-c8108b005d948e22 2026-09-10T05:04:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-grants-priority-review-for-roche-s-enspryng-for-mogad-an-autoimmune-dise-74fecb34511c53e2 2026-09-10T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stavros-nicolaou-represents-aspen-at-the-9th-annual-sadc-industrialisation-week-07118bf02b625030 2026-09-10T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/finnish-aq-biotech-raises-2-5m-to-scale-cancer-screening-in-china-4d00cc33ac6dddf2 2026-09-10T04:29:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/harbour-biomed-advances-long-acting-antibody-candidate-to-phase-3-trial-bb7175ea04a5f45e 2026-09-10T03:42:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results-1881334f1adeeee7 2026-09-10T03:34:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-remede-system-7f6e3ec0b271b2e3 2026-09-10T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kenanga-investment-bank-introduces-world-s-first-hang-seng-biotech-index-structu-2d2c97ee8f163699 2026-09-10T02:54:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-10T02:49:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanjing-zhongchun-biotech-rooted-in-the-ancient-capital-a-reliable-partner-in-fi-f233ef0f32fa8f8a 2026-09-10T02:36:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-d26bebab03c30cc8 2026-09-10T02:23:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/insilico-medicine-doses-first-patient-in-genesis-ipf-3-the-world-s-first-phase-i-e40660aaa25393ab 2026-09-10T00:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-9f35af525cd09cc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-29706f5bf24237ff 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-5e0d92994d60f5a4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-d81b0bf746dea1d5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-bed409cbf5ace142 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-0a8fecb54a3fc423 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-8ecf642e68d895e2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-1f9381361a06f286 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-fbc5f4932d6017a5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-9b2cd91149447d39 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-099ad11c1b7cf6fd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-af717744324c797a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-55971ce00f6a5b47 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-7c0c91083a2a7674 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-0da438f85c422491 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/green-innovation-gmbh-withdrawal-of-food-additive-petition-animal-use-d90074417ad7c799 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2027-091f27d76fcd85b3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-2abdf53dea0a6290 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-public-online-rou-60eabdf6f3844b70 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-mechanical-deviatio-e4a18073cc69ba43 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-temperature-regulat-1550b33975ad5831 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-extravascular-suppo-cc4f76058ba83528 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classificatio-95c9753661159e4c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-ear-nose-and-throat-devices-classification-of-the-cooperative-po-053f86715c0fa357 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-implanted-19651965512a4fdc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-vaginal-hydrogel-packing-cf0bb5f7ee0efe46 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-e53ed8cdd83debac 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-bc670a4d8a9047aa 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-to-the-senior-medicare-1c16ee7d1b83e6c7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-retrospective-analysis-of-clinical-outcomes-following-human-deviations-from-al-60989f4665caf7ce 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-function-of-angiotensin-converting-enzyme-inhibitors-in-chronic-kidney-disea-8f6ef8fb6d240f67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/introduction-fcc82029050d3cfc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/epidemiology-of-acute-kidney-injury-aki-and-sepsis-associated-aki-in-critically-b6d5977523dd237c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-telephonic-reminder-on-fasting-duration-in-children-undergoing-c-81dd7d56c74043e5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-sternomental-and-hyomental-distance-based-dynamic-airw-9b0a21c89b21e9a8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phantom-plethysmography-a-pulse-oximeter-artifact-caused-by-ambient-light-9d789979f52ddb2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/thoracic-continuous-spinal-anesthesia-for-prolonged-thoracolumbar-fixation-and-k-39160d2fd342c76e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/morphine-ketamine-combination-for-acute-trauma-analgesia-unanswered-questions-be-a688b64ea7fdcefb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutic-responses-and-6-month-clinical-outcomes-in-sarcoidosis-a-longitudina-1dfb2b94343d3422 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-patient-performed-cleaning-methods-on-the-integrity-of-1841900d0724de48 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-risk-factors-and-treatment-outcomes-of-diabetic-foot-ulcers-a-p-4373b3d863bde44d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-brain-natriuretic-peptide-and-intradialytic-hypotension-in-h-a365fbb4949ebe9d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/left-atrial-appendage-occlusion-vs-oral-anticoagulants-current-evidence-and-deba-5f809c5eb8e4f23b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/electrotherapy-in-pediatric-rehabilitation-a-structured-narrative-review-of-clin-d2236a91b304d8e6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cbct-based-anatomical-assessment-of-lingual-bone-availability-relevant-to-the-me-4d89c9009e1b662a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personality-and-coming-to-terms-with-cancer-a-cross-sectional-study-of-five-fact-0ead1686b1643e4b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/circulating-interleukin-17-across-airway-disease-phenotypes-a-single-center-obse-2fdf11ea2437bca3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-age-on-success-of-3d-printed-cranial-remolding-orthoses-for-deformatio-9aa46e3dc891e64d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exercise-induced-bronchoconstriction-in-school-aged-children-born-very-preterm-p-ae54f67e30689774 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multilevel-mechanisms-and-clinical-efficacy-of-psilocybin-in-depression-treatmen-c152eb701a32b92c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/user-centered-design-approach-to-dynamic-clinical-decision-support-in-primary-pr-311b856abb73970d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-huang-et-al-accuracy-and-agreement-of-a-45-mg-versus-a-75-mg-13c-urea-c3adf5d3af9f3d93 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-new-treatments-in-pediatric-brain-tumors-a7ae81bda7df0329 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-mitochondrial-support-to-mitohormetic-readiness-a-micronutrient-centric-ext-f324d9fbecf27cf9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-ethanol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-patients-w-272a8ec4a97d9120 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-live-birth-rates-between-calorie-restricted-diet-and-metformin-pri-e6f52d6cd1926e2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shunt-pathophysiological-mechanisms-and-clinical-implications-of-ineffective-cir-3955f02cf56865e4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypericin-and-hyperforin-from-st-john-s-wort-are-potent-intestinal-ugt-inhibitor-10d289e1efb49df5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/foxc1-drives-lung-cancer-metastasis-and-functions-as-a-target-for-ai-enabled-ant-1defa9cda85e5e4f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-a-negative-trial-timing-molecular-residual-disease-and-antibody-biology-i-bb05374d7dd1fb5e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acupuncture-for-chronic-tinnitus-study-protocol-for-a-clinical-trial-with-audito-8863c954452a2b82 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/control-effect-of-dual-mechanism-myopia-control-lenses-on-myopia-in-children-and-7da4cb5525ea95aa 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-warrant-in-medical-llm-evaluation-459f9d52d16df761 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/presidential-inaugural-address-2026-expanding-computer-based-testing-strengtheni-15fe341fe4ecbd79 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-and-the-right-to-a-fair-trial-in-the-context-of-ensuring-b0afc141737b48ad 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-contribution-of-instagram-influencers-to-drug-literacy-a-digital-communicati-9b940a97b351f178 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-year-comparison-of-three-maintenance-doses-of-vitamin-d3-600-1000-and-2000-i-7d271c298d361625 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-drug-interactions-and-pharmacological-complexity-as-prognostic-determinants-36411921172495c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-thyrotropin-meets-growth-hormone-clinical-challenges-of-a-mixed-gh-tsh-secr-582838b0171f14b7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-clinical-and-cephalometric-assessment-a-comparative-review-b29ec57ce2d2f40a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photodynamic-therapy-of-onychomycosis-modern-photosensitizers-and-clinical-effic-64ce2376748684d7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209aca 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440ba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faed 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaea 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spotlighting-rising-researcher-lucas-attia-from-drug-nanoparticle-engineering-to-80d678c9fb2b6243 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-changes-in-cardiovascular-measures-following-speed-agility-and-quick-7d38e12c591165cb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-of-artificial-intelligence-chatbots-in-restorative-dentistry-a-compa-9b191fa00532fd63 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sterile-neutrophilic-pseudomembranous-conjunctivitis-associated-with-tisotumab-v-d38695f0b78e7a1b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-two-tooth-whitening-treatments-a-randomized-split-mouth-clinical-t-c0c6e1e2d0ef8771 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-observation-on-four-finger-pushing-manipulation-combined-with-acupunctu-a2814a38ddb8384a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-inter-assay-discrepancies-and-regression-derived-correc-3228176469d0ff16 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-prediction-model-for-self-harm-after-adolescent-traumatic-brain-injur-e24ad5ae8d0cc3dd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vancomycin-rescues-sensitivity-to-isoniazid-in-clinical-isolates-of-drug-resista-e8b7cbd1c4a03064 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-tests-don-t-fit-the-rules-regulatory-challenges-for-agnostic-metagenomic-ne-331f129d805b783b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-techniques-and-complications-associated-with-pterygoid-implants-a-sy-83a100367b3cf247 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/diagnostic-yield-of-brain-mri-in-pediatric-short-stature-hypothalamic-pituitary-74fd0b47c4324c38 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-development-and-initial-validation-of-the-perinatal-intrusions-interpretatio-e0c5c555f7035197 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/heart-failure-among-people-with-hiv-prescription-of-guideline-directed-medical-t-13740b1e548b1bb9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-user-centric-patient-educational-intervention-in-clinical-practice-helping-wom-65d17fa745ccd8e6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autophagy-activation-in-granulosa-cells-as-a-mechanism-of-astaxanthin-action-evi-837d5d6cedcc31a1 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/silk-sericin-fibroin-composite-drug-delivery-systems-for-lung-cancer-mechanistic-8a8fa26cb15838c7 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-guided-imagery-supported-psychoeducation-on-self-esteem-perceived-str-081b38975cbead8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/applying-natural-language-processing-to-address-healthcare-bias-using-care-sd-to-ef4b247727690352 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-lipid-ingestion-is-sensed-the-mechanisms-underlying-intestinal-hormone-secre-22afd06b3217a312 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pre-treatment-prediction-of-ebv-dna-status-in-nasopharyngeal-carcinoma-using-ce-a68cbee4efda910c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-artificial-intelligence-and-quantum-chemistry-for-sustainable-pharma-2d6f3ac18e807696 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual-care-55d47fa59cf1d06d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/aptamer-functionalized-dna-frameworks-as-targeted-drug-buffers-for-concentration-80b9dd9403406b46 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trust-and-the-reliability-of-ai-algorithms-for-clinical-decision-making-support-9e4b561742c5eac6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/potenzial-und-herausforderungen-von-large-language-models-in-der-klinischen-ents-aab5af7bbb512e77 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-deubiquitinating-enzyme-regulatory-network-in-malignant-progression-of-breas-1ae6f24cf43a9983 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-laboratory-and-radiological-factors-associated-with-posterior-reversibl-ada55e4fd84835f5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agreement-between-artificial-intelligence-and-periodontists-in-the-detection-of-19457d539500c908 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preserving-beta-cell-function-in-children-and-adolescents-with-newly-diagnosed-s-57b94481282b6072 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07813208-ph-all-in-chinese-children-diagnosis-treatment-and-survival-eb09a4a0ca15599d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812636-tirzepatide-and-levonorgestrel-iud-therapy-for-ein-and-early-stage-e-62fa618027a35796 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812402-the-effect-of-factors-affecting-bone-mineral-density-measurement-res-2973f03482cf3684 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07812142-retrospective-analysis-of-the-second-year-of-safety-surveillance-of-2d8c760820377312 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07811817-the-outcomes-of-sympathetic-cardiac-denervation-on-postoperative-atr-6898ffb279287097 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07807579-impact-of-dexmedetomidine-versus-propofol-on-intracranial-pressure-i-3ebfbb09eb810a2c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07802639-treatment-for-asymmetric-crying-facies-6a5482072b6db189 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796880-neoadjuvant-culmerciclib-combined-with-endocrine-therapy-for-hormone-236a6ff0dd7aaab3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07757334-trauma-focused-group-therapy-for-adults-with-trauma-related-symptoms-938497b4eae7f668 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07755800-impact-of-an-arginine-containing-toothpaste-on-the-subgingival-micro-a66ba8f161165838 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619014-comparison-of-the-effectiveness-of-miswak-and-manual-toothbrush-in-r-61752a5ba9670351 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07510737-the-effect-of-cross-training-on-clinical-and-functional-outcomes-in-7510d95205e24ef6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07490925-transpulmonary-pressure-guided-mechanical-ventilation-strategy-in-ri-67a89935b4d97fdb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07403487-phase-ii-trial-of-rc1416-injection-in-asthma-3a70f1e833dd11d1 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07391774-testing-whether-hormone-therapy-with-ribociclib-is-as-effective-as-c-950c4ddcb9c97097 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07346768-evaluation-of-anterior-neck-ultrasound-in-predicting-difficult-airwa-e45c6f540528963b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07301333-a-study-of-single-and-multiple-doses-of-hrs-6257-in-healthy-subjects-b397d0795f6d989a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07252245-pre-hospital-triage-of-patients-at-intermediate-and-high-risk-for-ac-80a6b5fc1f6fe45d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07195734-testing-the-addition-of-chemotherapy-or-chemo-immunotherapy-to-the-u-eaef4d5ec3a3e699 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07000253-timing-of-comprehensive-local-treatment-after-first-line-systemic-th-342d10d4c9ccc441 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06991751-a-natural-history-of-cardiometabolic-disease-among-us-bhutanese-deve-74080274b3baf1da 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06834984-ritual-synbiotic-a-dietary-supplement-designed-to-impact-gastrointes-812e09906b02af8f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06728592-emergency-stroke-unit-for-acute-cerebrovascular-events-a-prospective-ce25f2838db0d108 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06687369-a-study-to-compare-pharmacokinetics-efficacy-safety-and-immunogenici-f27ee34c79201243 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06646627-clinical-trial-of-autologous-b7-h3-car-t-cells-in-reoccurent-platinu-64da8d624df467f8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06485622-outcome-and-improvement-of-different-treatment-in-arteriosclerosis-o-9e6f55f052856edc 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06473857-design-implementation-and-evaluation-of-an-intervention-within-video-e815a59dea39ec4a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06360822-increasing-equity-in-lung-cancer-screening-b4a214aae70631f2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06345079-cessation-of-somatostatin-analogues-after-prrt-in-mid-hind-gut-and-p-ed61837c12c16b51 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06339177-hemophagocytic-lymphohistiocytosis-hlh-evaluation-and-research-of-cl-98ebc57a25bf0463 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06277401-exercise-in-patients-with-hypermobile-joints-and-knee-pain-b27705bc9cf79ce5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06040125-debunking-the-frailty-sarcopenia-adt-axis-in-metastatic-prostate-can-128757a54a83f5c8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06024746-a-study-to-determine-the-efficacy-and-safety-of-finerenone-and-sglt2-da7f590809573fe2 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06014827-biologically-guided-radiation-therapy-bgrt-and-stereotactic-body-rad-d9c90c38d3384a71 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05960461-families-moving-forward-fmf-connect-pro-for-mental-health-providers-c10658528e77ed2e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05726526-ckd-specific-telemonitoring-platform-to-minimize-adverse-outcomes-in-6ed1dd4b247198a9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05692687-a-post-market-clinical-study-to-evaluate-the-safety-and-performance-d750517fead1c294 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05564390-myelomatch-a-screening-study-to-assign-people-with-myeloid-cancer-to-24330c5ca77ac0cb 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05413343-clinical-study-on-monitoring-the-plasma-concentration-of-ceftazidime-1798b3f69bd38b0f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05027386-apatinib-mesylate-combined-with-it-regimen-for-the-treatment-of-recu-f8c8487f9f0e5b11 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04864054-gpc3-targeted-t-cell-therapy-ect204-in-adults-with-advanced-hcc-4ac96ef3c3032db6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04288869-change-in-brain-perfusion-during-induction-of-general-anesthesia-0597049227a260ac 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03964532-talave-induction-talazoparib-followed-by-combination-of-talazoparib-ef82b804574ba6bf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03952637-a-phase-1-2-study-of-intravenous-gene-transfer-with-an-aav9-vector-e-a43bede94f74abe6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03424005-a-study-evaluating-the-efficacy-and-safety-of-multiple-treatment-com-7cf230def61e35fe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03077061-peri-implantitis-reconstructive-surgical-therapy-8ced217a0ad67979 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01471834-verification-of-the-efficacy-and-safety-of-the-barostim-neo-system-i-92140cd6f7208e5a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01426165-effect-of-magnesium-sulfate-infusion-rate-on-magnesium-retention-in-d3fa07dc21a48b44 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01087320-genome-medical-sequencing-for-gene-discovery-3e5a241c98c3dee8 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01029873-quilt-2-008-study-of-alt-801-with-cisplatin-in-patients-with-metasta-aa0122aaeeb4afc4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-target-price-raised-to-650-000-as-roche-deal-value-reflecte-7b981f6d3cd04d61 2026-09-09T23:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-after-aspire-miss-and-genglycos-win-has-valuation-3ffec4f293a82118 2026-09-09T23:28:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/portage-biotech-alp-financials-2026-income-statement-and-balance-sheet-alp-a532834d0e460662 2026-09-09T23:15:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868 2026-09-09T23:04:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-recommendat-ebbddaf59e9d3532 2026-09-09T23:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rebuilding-mexico-s-pharmaceutical-supply-chain-3e5a86b66630a924 2026-09-09T22:42:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/potential-pill-for-peanut-milk-egg-allergies-enters-phase-3-trial-9b77f26228e19997 2026-09-09T22:35:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-1ec522bb7e31fbae 2026-09-09T21:53:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-2bbc103d0de45256 2026-09-09T21:46:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/biden-era-by-mail-abortion-pills-can-t-be-halted-despite-safety-data-gap-appeals-e16ccb2f49768bd5 2026-09-09T21:39:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-four-senior-fda-officials-in-leadership-reorganization-54cf11cc363bef01 2026-09-09T21:34:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/generation-park-is-creating-a-national-pharmaceutical-hub-in-houston-bba29ce5588183be 2026-09-09T21:10:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-annalina-che-the-scientist-behind-biotech-start-up-darkfin-labs-c8d101f77eaedcec 2026-09-09T20:08:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-in-patients-08ecec56915041b8 2026-09-09T20:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shareholders-back-every-proposal-at-purple-biotech-ppbt-2026-meeting-8cc35989e741aa3e 2026-09-09T20:02:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-transfer-success-drivers-and-obstacles-explained-f93565e6205cc9ff 2026-09-09T19:36:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-6e6421b7f6e08843 2026-09-09T18:54:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-c198555d2578e70f 2026-09-09T18:35:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-6e050300f86774f7 2026-09-09T18:31:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/wall-street-slashes-dyne-therapeutics-targets-after-novartis-dm1-trial-failure-f71e254e2955835d 2026-09-09T18:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nueva-convocatoria-para-realizar-practicas-preprofesionales-0a0fa80b13f1b170 2026-09-09T18:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-and-tunisian-officials-break-ground-on-renovation-of-ministry-of-health-phar-ba2e86b24a145546 2026-09-09T18:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/leukemia-drug-data-suggested-a-different-way-to-treat-diabetes-a-new-biotech-wil-951cf12440ea5591 2026-09-09T17:57:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/cualtos-opens-registration-for-the-bachelor-s-degree-in-pharmaceutical-chemistry-cd37687b38cd07c5 2026-09-09T17:22:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36f 2026-09-09T16:54:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-skeptical-that-louisiana-can-sue-fda-over-mifepristone-being-maile-a16892c426e35ef1 2026-09-09T16:51:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-today-satya-niketan-collapse-a-wake-up-call-to-act-but-why-wait-for-tragedi-9e4d71030a910565 2026-09-09T16:37:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-s-r-d-commercial-approach-shifts-amid-global-policy-evolution-65d9e6dd72fa76dc 2026-09-09T16:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-releases-upgraded-degasi-inline-degasser-range-147cc76d79d3987c 2026-09-09T16:32:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-12b843a0aabf818f 2026-09-09T16:21:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-75ef1e4053d689b2 2026-09-09T16:21:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alpha-genesis-backs-biotech-startups-with-50m-agi-ventures-fund-99f88ef051673c6f 2026-09-09T16:19:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1 2026-09-09T16:15:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-spins-diabetes-work-into-a-lilly-backed-biotech-startup-ee94fc840173114d 2026-09-09T16:14:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-9th-b898d2190cfcaabb 2026-09-09T16:07:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/ima-group-to-showcase-all-in-one-solutions-at-cphi-milan-8f37948273925931 2026-09-09T16:06:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-inside-the-latest-mfn-deals-signed-by-nine-drugmakers-03b08aa8809af0e0 2026-09-09T16:03:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/one-state-s-abortion-ruling-could-affect-all-50-0b0a9758c1ef7862 2026-09-09T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/four-biotech-stories-heating-up-right-now-f51da81af50695d6 2026-09-09T15:55:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-fills-four-senior-roles-including-top-officials-for-drugs-vaccines-and-tobac-12068fd76e56966c 2026-09-09T15:55:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-impact-assessment-8e5c43f577238ed7 2026-09-09T15:46:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-designates-raju-willener-as-cfo-801ec29de9a56a5a 2026-09-09T15:46:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medical-device-licensing-regime-impact-assessment-27313ede92bd836d 2026-09-09T15:46:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-050bf26e4894b2ca 2026-09-09T15:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-mhra-reforms-impact-assessments-d4da977182c6d068 2026-09-09T15:46:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-pharmacy-appeals-process-impact-assessment-a5f9700a9414e0ed 2026-09-09T15:46:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-section-75-of-nhs-act-2006-impact-assessment-5f9809bc31c7871f 2026-09-09T15:46:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-patient-safety-measures-impact-assessments-092abe2dadcce996 2026-09-09T15:46:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-role-and-functions-of-the-restructured-dhsc-fact-sheet-89c454d704f2bab3 2026-09-09T15:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-structural-measures-to-icbs-and-foundation-trusts-impact-assessments-7a34cf0996abe91d 2026-09-09T15:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-providers-fact-sheet-ad8fa072da7a9f6e 2026-09-09T15:46:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-fact-sheet-6de16d25a204e1ef 2026-09-09T15:46:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-impact-assessment-00de0de68dc58510 2026-09-09T15:45:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-equality-impact-assessment-61dc9515198e3cd9 2026-09-09T15:45:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-impact-assessments-summary-744fa7c4f88e3806 2026-09-09T15:45:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-equality-impact-assessment-a15632314deab107 2026-09-09T15:45:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-equality-impact-assessments-summary-8eeb40343ce210f9 2026-09-09T15:45:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/wall-street-weighs-impact-on-dyn-stock-post-novartis-phase-3-failure-rbc-says-th-ab7d5395de69c328 2026-09-09T15:41:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-equality-impact-assessment-33c1a8f7b32a87b9 2026-09-09T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medicines-and-medical-devices-regulatory-reforms-fact-sheet-7269b5ea8e00e2df 2026-09-09T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-s-del-desiran-misses-primary-endpoint-in-phase-3-dm1-trial-99ce4a179960b851 2026-09-09T15:31:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-the-biggest-ndc-12-risk-sits-in-the-handoffs-3d5e69a55011a8ea 2026-09-09T15:23:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-bea04f575ed28a14 2026-09-09T15:08:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-appeals-court-hears-baseless-challenge-to-the-abortion-pill-mifepristone-940486b7c14cf63f 2026-09-09T14:56:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/beeline-medicines-19dae1080a3df20c 2026-09-09T14:52:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574 2026-09-09T14:46:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-account-teams-call-claimguardrx-their-smartest-teammate-24ca28a696436c27 2026-09-09T14:24:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-proprietary-llm-behind-claimguardrx-s-detect-and-respond-engine-756b5ec033050dc5 2026-09-09T14:24:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-creates-lilly-backed-spinout-armed-with-50m-to-advance-next-gen-diabetes-th-f97b4a180f77d74c 2026-09-09T14:20:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/macrogenics-inexpensive-adc-tce-biotech-with-multiple-catalysts-ahead-nasdaq-mgn-3992c5961012659d 2026-09-09T14:15:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/ideaya-biosciences-doses-first-patient-in-phase-3-trial-d00198a17e0c725f 2026-09-09T14:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/leerink-partners-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-b4f76e98ec172cbd 2026-09-09T14:08:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-transition-to-home-why-confidence-is-critical-to-patient-success-f53fe705f45b7442 2026-09-09T13:58:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-bondwell-partner-on-texas-biotech-d0f4351f2a06e4f3 2026-09-09T13:56:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-order-directs-federal-push-on-psychedelic-drug-research-and-review-7a02808d8f427079 2026-09-09T13:48:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/acrp-launches-2026-27-scholarship-and-grant-application-season-4a9b54371cfd920f 2026-09-09T13:45:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/orexin-discoverers-awarded-prestigious-lasker-award-0889c17faef35301 2026-09-09T13:43:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/luma-locks-down-15-year-410m-fund-for-life-science-investments-2229e6c1a7656df9 2026-09-09T13:43:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-31-august-to-4-september-2026-4fbb5b1daae2c350 2026-09-09T13:41:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/nutriband-ceo-gareth-sheridan-to-attend-inaugural-nasdaq-lab-biotech-summit-1307e17da858ae68 2026-09-09T13:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tyra-rolls-toward-pivotal-cancer-study-even-as-stock-deflates-06453e4e0f97fa39 2026-09-09T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/five-years-at-bio-mexico-gaining-ground-in-global-biotech-ec0a6f6068da0a75 2026-09-09T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92a 2026-09-09T13:19:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-cf7873ac652d7f27 2026-09-09T13:09:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-c106ca309e8a6793 2026-09-09T13:09:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ocugen-doses-first-patient-in-phase-3-ga-gene-therapy-trial-32970696c462f25b 2026-09-09T13:06:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-734f447a25d821db 2026-09-09T13:03:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/viral-haemorrhagic-fever-acdp-algorithm-and-guidance-on-management-of-patients-a442005e4b179daf 2026-09-09T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-p-39acc0eee159b7fc 2026-09-09T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/suddenly-this-summer-biotech-breaks-open-with-drug-approvals-ipos-will-it-last-25bef14c1bde5876 2026-09-09T12:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-258d162076f199f0 2026-09-09T12:42:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/nordic-biotech-ceos-reveal-secret-to-major-funding-and-pharma-deals-a3efea1f52140818 2026-09-09T12:37:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/don-t-ignore-the-insider-selling-in-biomarin-pharmaceutical-c392d2b0a526d595 2026-09-09T12:36:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nitrosamines-from-detection-to-understanding-c0e645b8909bb3aa 2026-09-09T12:36:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-dispuso-la-baja-de-habilitacion-de-la-firma-rehue-s-a-y-prohibio-sus-produ-95c8696ba780c6c0 2026-09-09T12:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmasource-podcast-how-exoz-is-running-a-10-cdmo-rfp-for-cdmo-selection-3a007b19e8cf1ab3 2026-09-09T12:31:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-paid-pilot-will-test-trinity-biotech-cooling-fluids-in-ai-data-centers-7fd633709f73fc8c 2026-09-09T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/over-1-5-billion-to-help-nhs-withstand-year-round-pressure-cbf84c3935b064e9 2026-09-09T12:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-narcolepsy-drug-showed-median-reductions-of-up-to-88-8-in-sudden-muscle-loss-a-0ff7d04798652a97 2026-09-09T12:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8 2026-09-09T12:13:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/atmospheric-nox-may-contribute-to-ndsri-formation-study-shows-717a069d3a62c417 2026-09-09T12:12:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-back-to-back-phase-3-failures-for-pelacarsen-and-del-desiran-send-share-2bac2be2f578a969 2026-09-09T12:10:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/world-health-expo-to-showcase-trillion-dollar-growth-across-pharma-biotech-longe-6803da287ace71b1 2026-09-09T12:07:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-may-2e45bd7b86003737 2026-09-09T12:06:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-apri-b7f6f80136a72c29 2026-09-09T12:06:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-marc-a9688d88c3a30590 2026-09-09T12:05:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-febr-df1ca0002f7ddc6b 2026-09-09T12:05:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-june-a0324311fd4d4714 2026-09-09T12:05:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-july-e4a658a591d9a33e 2026-09-09T12:04:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-augu-e29136a0758c031f 2026-09-09T12:04:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-dd9b886471b7e27e 2026-09-09T12:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-63ff575955c0b169 2026-09-09T12:04:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-janu-6665f6d4d545e2ad 2026-09-09T12:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-pays-50m-milestone-as-mrt-6160-enters-phase-2-for-sjogren-s-disease-168b743c3496ab83 2026-09-09T12:03:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-dece-b514e806327cec75 2026-09-09T12:03:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-nove-9bc61a228a7791a8 2026-09-09T12:03:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-b016e524e13c6091 2026-09-09T12:02:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-700ae1d4dc61471f 2026-09-09T12:01:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezera-announces-ruvonoflast-met-its-primary-inflammation-551bfbb3756d9d66 2026-09-09T12:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-3-f66515bf33b9f262 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/three-chugai-researchers-behind-the-discovery-of-hemlibra-for-hemophilia-a-recei-818232e0bd38792c 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veradius-unity-and-bv-pulsera-mobile-c-arm-system-9in-and-12in-versions-0cb1d977b3032a6a 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/philips-ingenia-achieva-and-intera-mr-systems-b7e6009e9e3fb961 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nodthera-inc-changes-name-to-rezera-inc-and-announces-ruvonoflast-phase-3-develo-e4a7e3b646456dbf 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/court-of-appeals-hears-oral-arguments-in-louisiana-abortion-pill-lawsuit-50fa9321f5302288 2026-09-09T11:50:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/ganesh-chaturthi-2026-mumbai-s-12-000-ganesh-mandals-under-fda-scanner-over-pras-be7950d397f186f7 2026-09-09T11:27:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/mirum-pharmaceuticals-hires-lmh-strategic-solutions-284e103ab1270aa8 2026-09-09T11:24:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-advertising-investigations-august-2026-0b95edb50287d7e6 2026-09-09T11:23:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/article-141-1-procedure-quarter-based-selective-dry-cow-therapy-dc21887708f5021b 2026-09-09T11:22:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/141-1-7a946e163c61ea87 2026-09-09T11:20:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-guidance-data-and-analysis-cf4d903cf180377a 2026-09-09T11:16:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-june-2027-bab1705385315cda 2026-09-09T11:15:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-september-2026-404dfd4156db3fd3 2026-09-09T11:15:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-9da1ba6971e41fb4 2026-09-09T11:06:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/kane-biotech-to-host-commercial-update-webcast-on-september-16-9a8886880a182539 2026-09-09T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/111-patient-eye-pain-trial-planned-by-okyo-pharma-nasdaq-okyo-84beab271f892e82 2026-09-09T11:00:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/algorithmic-tool-may-improve-screening-of-patients-for-an-alzheimer-s-clinical-t-562efba4ceb9605d 2026-09-09T11:00:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-is-still-reviewing-rezolute-s-experimental-drug-no-timeline-is-set-cf406d8464aac8e4 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beeline-flies-into-ph-3-as-oral-lupus-drug-soars-past-placebo-303874c2252c60b3 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-cancer-biotech-twostep-gets-62-5m-to-take-twist-on-adcs-into-clinic-817e254766ff52c2 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-0849105330920f96 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schrodinger-births-new-immunology-and-inflammation-biotech-tectora-therapeutics-3c2ecfcd5bb63fb8 2026-09-09T10:58:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/solstice-rises-with-225m-series-a-to-advance-next-gen-ctla-4-immunotherapy-into-398cbf270d73588b 2026-09-09T10:58:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-manufacturing-questions-facing-chinese-biotech-cf50d2874a8599be 2026-09-09T10:56:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-food-order-for-festivals-what-maharashtra-fda-commissioner-said-3dd813ddcd70dbc5 2026-09-09T10:54:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/moonwalk-banks-70m-to-progress-sirna-therapy-for-obesity-de269d2e1175ff14 2026-09-09T10:50:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/unparalleled-opportunity-sandoz-embarks-on-ambitious-biosimilar-growth-strategy-676c4323204a4fcf 2026-09-09T10:49:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-deve-9e7da1cb20ba16a8 2026-09-09T10:46:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-rapid-acting-short-duration-inhaled-treatment-is-being-developed-for-weight-ma-e383768e6e897a31 2026-09-09T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-6da5752584aa882a 2026-09-09T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-6902f574353aeb80 2026-09-09T10:28:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-makes-pharmaceutical-speaker-programs-illegal-f87d152b9ae8d979 2026-09-09T10:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-global-eye-cancer-trial-has-dosed-its-first-patient-529d4d314833481c 2026-09-09T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biden-era-abortion-by-mail-rules-face-key-test-at-appeals-court-hearing-0cd9e746f1b92012 2026-09-09T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nafdac-and-nhrec-announce-new-dates-for-mandatory-stakeholders-training-on-clini-c75adb4ff13bd3af 2026-09-09T09:53:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-among-independent-f32c88a42723b612 2026-09-09T09:50:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on-compan-7599cd1f8178910a 2026-09-09T09:47:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-4-returnees-from-an-ebola-affected-3451106449dc4cbd 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-3-returnees-from-an-ebola-affected-66d6f6455dcf6d66 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-2-returnees-from-an-ebola-affected-0ad9eb86ec575c6f 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-1-returnees-from-an-ebola-affected-24c7b8b02c106176 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-contact-matrix-for-returning-workers-scheme-and-non-uk-exposur-dedb115fc574e9fe 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-virus-disease-clinical-management-and-guidance-74343e283fe62dbc 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-returning-workers-scheme-public-health-advice-3f98a3a732b6c31c 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/barclays-upgrades-sagimet-stock-rating-on-acne-drug-potential-ae3e9d55d7da7baa 2026-09-09T08:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-chi-0c539f69c1cd457c 2026-09-09T08:04:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-sleep-apnea-measure-rose-10-4-with-an-experimental-drug-versus-49-2-with-place-90e8edbb76843343 2026-09-09T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-7689bcdaf1ae338a 2026-09-09T07:34:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/proteomic-aging-clocks-just-changed-what-a-phase-2a-trial-has-to-prove-2ad189fe17c2661b 2026-09-09T07:34:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicine-shortages-grow-in-iran-as-us-tightens-sanctions-blockade-ecd987fe722f5a4e 2026-09-09T07:20:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/5-questions-that-could-determine-alzheimer-s-next-chapter-16943d6949229332 2026-09-09T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-cracks-down-on-food-safety-violators-5fff85b007469683 2026-09-09T06:07:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-food-licenses-of-railway-catering-supplier-20-eateries-c5fd85665f97fc76 2026-09-09T06:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/steady-stream-of-crossover-rounds-stock-biotech-s-ipo-pipeline-dbbe4746af7c54ed 2026-09-09T04:17:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/ibento-ibento-report-on-the-pmda-hokuriku-branch-10th-anniversary-symposium-c1a0e57e7ec099d8 2026-09-09T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezubio-doses-first-patients-in-phase-i-trial-of-inhaled-respiratory-drug-rz-520-378d2a6eb465cc4d 2026-09-09T02:34:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/taiwan-s-obigen-pharma-to-unblind-phase-3-botox-trial-early-in-november-year-end-af705b30fbefc4cc 2026-09-09T02:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rezubio-doses-first-patients-in-phase-i-trial-of-inhaled-respiratory-drug-rz-520-1026a08765283c42 2026-09-09T02:01:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/wegovy-and-mounjaro-for-weight-loss-not-funded-a2a3ffb1738d2e00 2026-09-09T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinhan-securities-cuts-alteogen-target-to-520-000-after-novartis-aoc-phase-3-fa-972a02956e1cfc51 2026-09-09T01:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/many-different-paths-may-lead-to-a-role-in-clinical-project-management-96598feaeb50c516 2026-09-09T00:39:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/click-e-stock-one-novartis-new-drug-fails-phase-3-target-price-for-alteogen-lowe-7cafc5a1c226a35d 2026-09-09T00:23:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-9e8f3bd2a58b229c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-0a518003195b02c6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-pro-bff9d18f307f05a1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-es-b6fb3f98dd33049b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-hum-9e81e95c6000ebb0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-99f349f787d2f97e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andem-d38ea0d42ee8ba36 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pre-8f9c9e790ba2b6a8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anzup-eeb61cd6a595bf0b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ankti-9840243fd9e98d18 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-bee1e53401727a8f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reorganization-of-the-national-center-for-immunization-and-respiratory-diseases-588d95ecfd03eea8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tips-for-dealing-with-empty-nest-syndrome-64aa3c260d31a871 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cleveland-clinic-partners-with-luminai-to-transform-health-system-operations-8b1951904a6aedef 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-70-000-reassessing-the-global-fontan-population-through-citation-chain-an-b1ba1fb432aad77c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/estimating-and-predicting-clinical-trial-outcomes-in-china-f00f8b31650910e0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/intranasal-midazolam-vs-mouth-dissolving-clobazam-in-terminating-seizures-a-rand-99ac18ed68820c9c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/associations-of-baseline-neutrophil-to-lymphocyte-ratio-with-efficacy-and-toxici-c96f347b709d5107 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neoadjuvant-pertuzumab-biosimilar-hlx11-versus-reference-pertuzumab-for-early-st-7808b92e0e1149cf 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapeutics-candidates-and-repurposing-strategies-to-target-parkinson-s-disease-96683c528f323412 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neo-adjuvant-approvals-for-solid-tumors-by-the-us-food-and-drug-administration-2-756ed3abf614efc6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-phase-3-trial-of-vosoritide-in-children-with-hypochondroplasia-6de4f09ea4b05915 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-i-helicobacter-pylori-i-infection-with-insulin-resistance-tumor-n-316790c378779761 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenomenology-in-pediatric-nursing-lessons-from-studies-of-mothers-caring-for-ch-4f3fffea388d6bfe 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/utilizing-a-smartphone-application-for-perinatal-depression-screening-and-care-l-d1657f9c0ce56b10 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/network-biology-to-artificial-intelligence-building-the-next-generation-of-predi-7049814c4b1b0ea9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interactions-of-nanoparticles-with-structures-of-the-respiratory-system-nanopart-6e7d20d5c4593f8d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inhaled-nanoliposomes-for-treating-lung-disease-including-a-case-study-of-amikac-5c581901e1fef964 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-delivering-particles-aim-to-breach-the-blood-brain-barrier-6b0773077796d0f1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mechanical-basis-of-cortical-cataract-214599f9167e95ce 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07811128-leveraging-digital-health-solutions-to-collect-patient-reported-outc-de9c163ffaa5b58e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810855-using-bedside-ultrasound-to-understand-fluid-management-in-patients-f01e5454fd815262 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810231-prospective-longitudinal-cohort-study-of-implant-age-pocket-plane-in-f1335f5a7fd090e7 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809542-brain-network-characteristics-of-pain-patients-based-on-magnetoencep-f1102e08355c2f4a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809438-a-comparative-performance-study-between-high-and-standard-resolution-a7b9283bcd325474 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809399-volumetric-hrct-in-stable-copd-patients-905336f1346cda49 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809087-feasibility-study-of-an-interactive-wall-based-intervention-program-68f2eb96ca9dbf6e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809074-mindfulness-and-self-compassion-intervention-for-ostomy-patients-due-928772f3ba63ee88 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07808645-wearable-sleep-eeg-and-auditory-stimulation-in-healthy-adults-a3f895f1435a9f4e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07803471-yiqi-fumai-lyophilized-injection-for-chronic-heart-failure-caused-by-a2f07156d8dd8c5f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07770919-continuous-theta-burst-stimulation-for-generalized-anxiety-disorder-a11ec2e143861103 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07755748-glaucoma-screening-to-enhance-at-risk-californians-health-survey-res-613aad5046be38a3 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07668518-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-53495f0e626ad570 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07667400-docetaxel-and-sx-682-in-recurrent-metastatic-head-and-neck-squamous-eb782075b524b62c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07645443-feel-good-a-multicenter-trial-of-a-mindfulness-based-group-therapy-i-e6b3a6106587bc2a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07524530-stem-cell-transplantation-for-participants-with-germline-runx1-assoc-f7c7537ec91ee762 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07509034-autologous-b7-h3-chimeric-antigen-receptor-t-cells-in-previously-tre-2b314a9db8642130 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07447557-study-of-intrathecal-elp-02-for-charcot-marie-tooth-disease-type-4j-9df85b59b7760510 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07436728-a-study-of-tak-505-in-adults-with-solid-tumors-0ceaf12c08fe7644 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07262983-evaluating-the-safety-and-tolerability-of-baricitinib-in-patients-wi-834c49c5b61fdd2a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07241377-a-study-in-healthy-adults-to-compare-the-bioavailability-of-epa-dha-04a145623e5fd712 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07234942-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-934403a64baf19fb 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07224763-study-to-evaluate-the-safety-and-efficacy-of-the-ggta1-ko-thymokidne-e7469684f1a340a9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07210398-mindfulness-based-cognitive-therapy-for-the-chronic-pain-early-cogni-a5c8ad0779df2ad7 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07205107-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-triple-combinat-c2ef75272e264556 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07166094-study-to-assess-the-efficacy-and-safety-of-rina-s-compared-to-treatm-654bf6bd00153589 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06851806-study-of-palivizumab-in-children-with-high-risk-of-severe-respirator-030ea64e3955972a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06825702-safety-tolerability-and-efficacy-of-intravitreal-kio-104-in-patients-8d4299ce7f4765dc 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06782308-tinnitus-patient-preferences-survey-717b4fa3f14c3c2b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06578520-effect-of-the-use-of-dapagliflozin-in-patients-with-refractory-heart-ed2d60e95fd26467 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06548412-ctx-009-with-gemcitabine-cisplatin-and-durvalumab-as-first-line-ther-2b2fdba90bbebbba 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06470048-a-clinical-study-to-evaluate-ianalumab-in-participants-with-diffuse-81b10aa4165bd17c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06410248-triapine-in-combination-with-temozolomide-for-the-treatment-of-patie-0cf1d97b4e719323 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06323161-a-research-study-to-see-how-much-cagrisema-lowers-blood-sugar-and-bo-7b5290a15f28fde0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06260228-home-based-self-management-and-cognitive-training-changes-lives-hobs-ff1e48edbb3a2369 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06235801-a-phase-i-ii-study-of-gilteritinib-and-momelotinib-for-patients-with-1fe17411a66cc840 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05706558-retrospective-review-of-esophageal-cancer-at-mskcc-cafd4ee1a7b70879 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05570253-a-study-of-sdx-7320-in-combination-with-eribulin-for-people-with-bre-7c04db2a9102a2ce 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05232071-placebo-controlled-proof-of-concept-study-to-evaluate-the-safety-and-9fcfbde442103736 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05037461-precision-radiotherapy-using-mr-linac-for-pancreatic-neuroendocrine-fcedc2d84f591031 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04847648-air-polishing-in-the-treatment-of-peri-implantitis-7fadfb7a67b10d53 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04542824-trial-of-the-safety-and-efficacy-of-epcoritamab-in-japanese-subjects-8f8b2e5edddf7421 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04124497-a-trial-for-relapsed-and-relapsed-refractory-multiple-myeloma-patien-96886e54e668bcc6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03625037-first-in-human-fih-trial-in-patients-with-relapsed-progressive-or-re-7c8817969428243d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03549754-icareme-global-registry-multinational-real-world-evidence-in-cardior-ca8b38986b5aecf0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03307109-quality-of-life-in-patients-having-a-prosthetic-joint-infection-2572312124caf8f4 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02890329-ipilimumab-and-decitabine-in-treating-patients-with-relapsed-or-refr-cc9d070597ff8255 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02767011-tele-health-electronic-monitoring-to-reduce-post-discharge-complicat-c84b8d01820bce9e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01568658-genetic-and-physical-study-of-childhood-nerve-and-muscle-disorders-f16cdfe7ad322553 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-27bba2ce08cb2b5c 2026-09-08T23:53:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-trial-wins-sent-roivant-and-pharvaris-higher-98c19d328893c1ff 2026-09-08T23:38:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/as-fda-sets-ai-principles-for-drug-development-how-much-evidence-is-enough-a883e1c3fce040a0 2026-09-08T22:40:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-administration-names-permanent-leaders-at-fda-amid-ongoing-controversies-b3c82c9c2a34e326 2026-09-08T22:38:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharvaris-stock-jumps-after-positive-hae-drug-t-4085528d18522778 2026-09-08T21:57:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-to-rule-soon-on-marijuana-rescheduling-as-billions-in-cannabis-tax-e164d6e9b92848d2 2026-09-08T21:19:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/semaglutide-improves-bmi-category-in-phase-3-pediatric-obesity-trial-0a553bf6e7f7c09b 2026-09-08T20:17:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-a-s-stock-nvo-closed-down-by-3-09-on-sep-8-facts-behind-the-movemen-bf3c0573fb832069 2026-09-08T20:15:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-announces-key-leadership-selections-at-fda-to-promote-innovation-reform-and-da223f20305656e3 2026-09-08T19:59:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-to-rule-soon-on-marijuana-rescheduling-as-billions-in-cannabis-tax-53e03398fc5994dc 2026-09-08T19:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-gets-fda-clearance-for-phase-2-trial-in-multiple-sc-6e1a50fab04737c7 2026-09-08T18:13:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-falls-10-as-novartis-trial-failure-clouds-a-cholesterol-drug-class-nvs-sto-577262ea46adae76 2026-09-08T17:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-suffers-third-clinical-setback-in-a-week-wiping-out-over-40-billion-in-aecba47d0f5a987e 2026-09-08T16:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-08T16:36:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-a-cannabis-business-is-betting-on-dogs-to-reach-fda-approval-e63e12a392c30ad2 2026-09-08T16:29:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-vaccination-for-older-adults-and-for-individuals-in-a-clinical-risk-a3c9fa73d91e326d 2026-09-08T15:28:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/house-advances-carter-s-bipartisan-bill-to-reduce-animal-testing-in-drug-develop-f90a2c9708224bfc 2026-09-08T15:28:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-enforces-zero-tolerance-with-major-food-safety-crackdown-a0e97e5aa54ea452 2026-09-08T15:25:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuevos-proyectos-de-consulta-para-la-opinion-publica-f60c4dde925aa14a 2026-09-08T15:16:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lp-a-horizons-1b5ea32d857530a1 2026-09-08T14:52:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-a66e726a10440e23 2026-09-08T14:47:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-pharmaceuticals-gets-85-price-target-des-88a596b142c0403e 2026-09-08T13:49:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/x4-pharma-gains-fda-agreement-to-cut-phase-3-trial-size-to-76-patients-86a2f6c69c45444e 2026-09-08T13:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exozymes-selects-curia-as-commercial-scale-manufacturing-partner-for-nct-e32fe23efc672768 2026-09-08T13:05:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overa-2f50edcb3c7d5463 2026-09-08T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-2025-46183ecdfec674cc 2026-09-08T12:46:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662 2026-09-08T12:44:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/wegovy-for-overweight-young-children-novo-nordisk-s-obesity-drug-shows-effective-3431f97d0f9e3263 2026-09-08T12:30:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/veru-advances-oral-sabizabulin-following-positive-preclinical-data-showing-poten-3888551e81843663 2026-09-08T12:28:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/liver-cancer-patients-appear-to-be-living-longer-in-a-can-fite-trial-4dcb429a7fce4ae3 2026-09-08T12:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vor-biopharma-vor-completes-enrollment-in-phase-3-trial-as-market-eyes-growth-po-6854d0a7bff59ab1 2026-09-08T12:18:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/enregistrement-des-antibiotiques-dans-vamreg-e-learning-pour-les-veterinaires-5fb5bf0d85ad7573 2026-09-08T12:16:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-12b-avidity-acquisition-hits-phase-3-speedbump-as-dystrophy-drug-disapp-81a38543b41b14c8 2026-09-08T12:12:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/xfor-gains-fda-nod-for-reduced-trial-size-in-pivotal-phase-3-study-dfe6bf454bee75c8 2026-09-08T12:10:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaning-4a747bc53373c024 2026-09-08T11:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-announces-next-stage-of-fda-engagement-for-phase-3-parkinson-s-disease-pr-86f2e64a80edb748 2026-09-08T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artiva-biotherapeutics-announces-planned-2026-data-readouts-and-phase-3-trial-in-d72d6fed3e722f8c 2026-09-08T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nature-medicine-features-a-briacell-trial-among-11-shaping-medicine-in-2026-a2c3aef4540443f1 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-seeks-fda-feedback-on-a-proposed-parkinson-s-trial-of-about-175-patients-ee88e950491954eb 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/briacell-s-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-can-339c6a459d143c72 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncologists-say-newly-approved-pancreatic-cancer-drug-is-a-breakthrough-for-trea-81381f05106e10cb 2026-09-08T11:26:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-readies-phase-3-trial-of-eye-pain-drug-urcosimod-90d050241783edad 2026-09-08T11:01:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-50-million-payment-is-coming-to-monte-rosa-as-novartis-starts-a-sjogren-s-tria-31715f4d196d2209 2026-09-08T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-new-trial-for-eye-related-muscle-weakness-is-planned-for-2027-vor-bio-finished-b45892b2c443c86f 2026-09-08T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phas-8624811f3ce076b9 2026-09-08T10:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-confere-e76ae3336b1268bc 2026-09-08T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5a 2026-09-08T10:02:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-issue-375-flu-special-2026-1a30d6fa07e93be8 2026-09-08T10:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/up-to-200-000-people-live-with-this-lung-disease-roivant-starts-a-new-trial-d037a53d1ec5911f 2026-09-08T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-fda-steps-up-drug-crackdown-in-maharashtra-complaints-jump-557-ecfe5acba6850e4a 2026-09-08T09:56:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-12bn-avidity-bet-falters-on-late-stage-del-desiran-flop-a07058258a6406e4 2026-09-08T09:51:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-0170da8a7075e9e1 2026-09-08T09:40:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-heart-drug-fails-phase-3-trial-cutting-genetic-ch-0570ea9380fbcdd9 2026-09-08T09:39:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-2b2822c02a7f5c39 2026-09-08T09:35:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/prac-d8971a24133f87f2 2026-09-08T09:07:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-people-infected-with-toxigenic-c-ulcerans-74755f86c69d844a 2026-09-08T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-evidence-reviews-8f54ff16e8d4cd78 2026-09-08T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ame-bridge-management-1a3a141ab51144fc 2026-09-08T08:16:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-major-novartis-falls-10-after-three-drug-trial-setbacks-92f853f4d5272a6c 2026-09-08T07:51:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-th-e4bacc39df389b5c 2026-09-08T07:40:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-bio-reports-phase-2-valiant-trial-results-showing-verekitug-reduced-sev-18afce1d16ed54f2 2026-09-08T07:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-369fe1ae5d30a5c0 2026-09-08T07:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-quarterly-dose-cut-asthma-flare-ups-56-versus-a-dummy-treatment-upstream-bio-p-5957ae35a18b8b3f 2026-09-08T07:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-effect-100-days-12-083-actions-as-maharashtra-fda-leads-biggest-s-d98c23d18ab152bc 2026-09-08T06:42:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/food-safety-chief-tukaram-mundhe-s-plan-for-festivals-in-maharashtra-8c168d932d6ebed2 2026-09-08T05:32:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-p-9cedb9c94f3df816 2026-09-08T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-data-says-about-tukaram-mundhe-s-100-day-stint-as-fda-commissioner-196f7cd7d48755cb 2026-09-08T04:03:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/bmc-medical-co-ltd-recalls-luna-g3-apap-model-lg3600-with-firmware-g3-2-00-76-du-49c4827bc368c793 2026-09-08T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-inspections-expose-drug-safety-gaps-e2b63ad181bd692b 2026-09-08T03:20:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/yakkyokukata-jp-drafts-september-2026-part-1-posted-58fb2b9570d86ac0 2026-09-08T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yakkyokukata-jp-drafts-september-2026-part-2-posted-7fc8f7827c7927a1 2026-09-08T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-3c9bb893b8f5ebb3 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-d43e989b55ee68c6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-filed-form-6-k-9a3be5d9cea2290a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mark-allen-d-d-s-rescission-of-final-agency-action-and-withdrawal-of-order-to-sh-4ff464311d7f3296 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-ba5586ce8851a924 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicare-program-town-hall-meeting-on-the-fiscal-year-2028-applications-for-new-e0882cd256184bcf 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-51525e15cfb1b3ee 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-945ea22744a88fc9 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-irvine-labs-inc-06b927a4afc4595e 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fisher-clinical-services-inc-4f126cd097473cf8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-cambrex-high-point-inc-e82f843236b1838a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fresenius-kabi-usa-llc-a380373346bbc5af 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stephen-bossenberry-m-d-decision-and-order-a19b15ba4f04fad0 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-andersonbrecon-inc-dba-pci-pharma-58475345f958d070 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-33d1d408902e2bdd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-data-and-specimen-hub-dash-euni-43d65c3b310c33ea 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-baloom-2-panthenol-hydro-airy-sunscreen-76166a8e1258bb36 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-jack-black-sun-guard-sunscreen-spf45-11d1342f09fc9fc4 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-gas-relief-mint-flavor-b180d559ff2535ed 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-henry-schein-povidone-iodine-prep-pad-81fbd0914690a99f 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-gocovri-82a404236e5a1a35 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mucus-relief-severe-congestion-and-cough-f710e7b1445ced68 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-remedy-antifungal-with-olivamine-51fd828d06101007 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-intense-therapy-lip-balm-basil-lemon-11c1c2c0cb6eab1b 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-fiber-laxative-6fe5768eb18749f6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-ibuprofen-0ab98dedd1f109b5 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-rizatriptan-benzoate-9cb7cd03cb346b6c 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-temazepam-1493397ecc75f9a7 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-telmisartan-and-hydrochlorothiazide-38097fca411de6b8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-freshmint-premium-anticavity-6130335239e19fe8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-fluticasone-propionate-and-salmeterol-diskus-90cafa84bcde75b2 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-jack-black-intense-lip-therapy-spf25-black-tea-and-blackberry-22eb3fa7f4dac033 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-ibuprofen-minis-e7d71de53a87003d 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-medline-e5f6e808cb6975c6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-63f74e54e64d4b8f 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-intense-therapy-lip-balm-pineapple-mint-4b142735c95284f8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-thyroid-support-113e8b12e807cefd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-dapagliflozin-34b4fff388ddc511 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-pepto-bismol-fast-melts-fresh-berry-flavored-f616d20ad8daef35 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-imatinib-mesylate-893a33ea1b0588f5 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-vicks-zzzquil-nighttime-sleep-aid-diphenhydramine-hcl-free-of-192ef96369f04157 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-clonidine-hydrochloride-f79a41c83c300454 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-prednisone-08ef9ceeba00368e 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-kids-have-mental-health-days-b366f95b902dfefd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-accelerated-share-repurchase-agreement-d3b6ea9ca8945a2a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bausch-health-and-yun-announce-expansion-to-mexico-and-across-additional-emea-ma-f40b7d30c789ecd7 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pr-siliq-brodalumab-injection-now-reimbursed-under-alberta-s-public-drug-plan-im-e79ea40f76db38fd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/outcome-definitions-in-clinical-trial-registrations-a-cross-sectional-study-80ea0dc761f2ea79 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adaptive-ai-based-mobile-simulation-for-drug-calculation-competency-in-nurses-a-a38487112b01837a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-pharmacokinetics-and-pharmacodynamics-of-the-glp-1-gip-gcg-receptor-agoni-732b3a954859f846 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/butylphthalide-combined-with-tenecteplase-in-mild-disabling-acute-ischaemic-stro-8632aa90834b8816 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systematic-review-and-meta-analysis-of-intrathecal-drug-delivery-systems-for-the-78fe51bd2837a2ad 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomised-phase-iii-trials-of-cancer-prevention-drugs-a-systematic-review-and-p-e0ab6c687137bfcb 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-bayesian-phase-i-ii-trial-design-to-optimizing-dose-schedule-regimen-with-comp-2fe1ae9d0f6e2108 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-various-types-of-remineralizing-agents-on-the-remineralization-of-mild-6e735d880cd42199 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-microdrop-administration-using-a-bottle-adapter-of-2-5-phenylephri-1bd95ea7d3830788 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4 2026-09-07T15:38:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7 2026-09-07T14:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/only-around-half-of-primary-school-children-got-their-flu-vaccine-last-year-403f49a5bd04d397 2026-09-07T11:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2-2026-3c227aa9e7354928 2026-09-07T11:21:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/tobacco-and-vapes-packaging-appearance-and-display-b0f65b22298b2fc9 2026-09-07T11:19:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-a3d36d0f75424a9d 2026-09-07T11:11:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/mdd-class-i-ndi-passive-sphere-b7d0605889498eca 2026-09-07T10:03:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-41-report-data-to-week-40-dat-57a8ff892a5702f4 2026-09-07T09:40:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-4-october-2026-3416de2db5fbba30 2026-09-07T09:40:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-joint-programme-on-rare-diseases-d53cc8321f2dea5f 2026-09-07T09:40:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-harmonised-approach-to-early-feasibility-studies-for-medical-devi-0fb60975f2bf9da6 2026-09-07T09:40:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-41-report-data-to-week-40-data-up-t-544b20cee08c6ce5 2026-09-07T09:32:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-healthy-adaptation-to-pregnancy-postpartum-and-parenthood-82c4989530fdfda2 2026-09-07T09:25:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-lpt-laser-based-proton-therapy-syslpt-laser-based-proton-therapy-6966003adb9cf5cc 2026-09-07T09:24:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/driving-digital-transformation-amanda-strydom-on-women-technology-and-leadership-b25e6893da42d72b 2026-09-07T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49b 2026-09-07T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amarin-group-esg-3-9-ftse-russell-ea572dc6a605d4a4 2026-09-07T07:35:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-37-report-data-to-week-36-dat-12867e0648495a43 2026-09-07T06:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/11-jbda-1e862f8e99770ad1 2026-09-07T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-achievement-related-to-chugai-originated-nemolizumab-receives-the-11th-698ca4f032fd30e5 2026-09-07T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hand-sanitizer-vanilla-frosting-502a8098e1a85c7c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-nadolol-9ecde2dfb8ab0283 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-american-safety-and-first-aid-triple-antibiotic-73419f5abf1f0e8e 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-american-safety-first-aid-a829d4721e66769d 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-lady-speed-stick-24-7-fresh-fusion-3cc457ca2f39b640 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hydrating-mist-hand-sanitizer-with-silicone-keychain-holder-be-864d678e71f2b91f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-medi-first-topical-analgesic-3c8148ed4f999e88 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-pain-relieving-lidocaine-patch-bf93f3783ab22813 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-candesartan-cilexetil-b916f82c8372ddec 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mycophenolate-mofetil-b26da168ebd7aaa8 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hydrating-mist-hand-sanitizer-with-silicone-keychain-holder-si-9ffe521131db9c95 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hsenjt-arnica-bruise-cream-3f2dbcb573a9d9c2 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hsenjt-antifungal-cream-b03d186973378fab 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-bzk-antiseptic-towelette-7757b41c536188cf 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-sting-relief-pad-b2fae5b78e3baa71 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-alcohol-prep-pads-medium-sterile-06e2f1ee977c552c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-3a33edb2c5e2a501 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-speed-stick-power-ultimate-sport-7bc931b75bd52c25 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hand-sanitizer-cherry-sundae-d156d9e332eb3a64 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/survey-reveals-how-social-media-influences-men-s-health-pkg-329128b04c75c02f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanoparticle-based-strategies-to-enhance-psma-targeted-radioligand-therapy-a-rev-635a306c2914999f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports-simu-7be6a31c09a0d1b6 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salovum-reduces-mortality-in-isolated-severe-traumatic-brain-injury-a-randomized-f5280cc30cebfe6c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/use-of-the-bacterial-lysate-om-85-for-the-primary-prevention-of-wheezing-lower-r-daaaa4b1cdcd0cc5 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-lebanese-community-pharmacists-perceptions-and-practices-towards-p-29b4dbe8992d3edd 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-antidepressant-effects-of-the-mglu2-3-receptor-antagonist-ts-161-in-treatmen-252e248060ef67c5 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-fixed-dose-combination-therapy-with-cilostazol-and-rosuva-6f26c99c15c20bdb 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adjunctive-corticosteroids-in-herpes-simplex-virus-encephalitis-a-meta-analysis-e715ee16f58019ab 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/low-dose-ticagrelor-combined-with-aspirin-for-preventing-early-neurological-dete-8818d98d390612bd 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/selecting-vehicle-comparators-in-dry-eye-disease-clinical-trials-implications-fo-71d14de03c0ea035 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-a-multimodality-digital-health-intervention-to-c65082810d3a9f7c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-noicaky-fungal-nail-patches-c59b3d0016266246 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-skin-wart-remover-liquid-4a1fa90f63dc48d5 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-inlifay-antifungal-1b0d8445adbc37b5 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-versacloz-84957927c389ee11 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-registry-based-perspective-of-interventional-clinical-trials-for-duchenne-musc-9f2fc0f042f3f538 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enhancing-evidence-generation-by-linking-randomized-clinical-trials-to-real-worl-5d94e8e18f9c4ad2 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-invisible-to-enrolled-how-artificial-intelligence-is-reshaping-clinical-tri-53e62a54872a53c7 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-and-scientific-challenges-in-paediatric-oncology-d3b46ab83794e42f 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-recasts-drug-packaging-oversight-with-science-and-risk-based-container-closu-212514b16ec9a406 2026-09-05T14:29:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/oric-stock-holds-steady-as-biotech-eyes-next-trial-and-earnings-0490ce6768597bd1 2026-09-05T14:15:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/vrxa-jumps-as-traders-focus-on-biotech-breakout-setup-ffe5bbb195e962d9 2026-09-05T14:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/annovis-bio-stock-reacts-to-webinar-plan-and-steep-discount-to-analyst-targets-60ea8056814b23fb 2026-09-05T14:02:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-healthcare-professionals-view-greener-pharmaceutical-manufacturing-favo-86972c80169790db 2026-09-05T12:58:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/synh-stock-reflects-syneos-health-s-move-to-go-private-bd6ccbf69dfad23d 2026-09-05T12:31:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/symbiosis-pharmaceutical-services-appoints-jos-vergeest-as-senior-business-devel-90c6b0f056e0860b 2026-09-05T12:29:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-ms-pill-that-beat-standard-therapy-and-cleared-the-safety-bar-its-rival-coul-59dc69ca9441f4d0 2026-09-05T12:23:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/before-the-first-molecule-making-better-target-and-modality-decisions-44248c637b5c8dfc 2026-09-05T11:59:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/bpom-invites-pharmaceutical-industry-to-bolster-clinical-trials-3a5d10ffdcf5d92b 2026-09-05T11:47:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/personalized-cancer-vaccine-breakthrough-ignites-sequencing-sector-tempus-ai-s-p-d35b5a3721aae31d 2026-09-05T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-drug-for-alexander-disease-247a4f900fe6e339 2026-09-05T10:47:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/crispr-therapeutics-gains-fda-approval-for-casg-2f0879fdfbacbdd9 2026-09-05T10:40:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-beijing-sl-pharmaceutical-co-ltd-class-a-stocks-bbd678d351a029d1 2026-09-05T10:30:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/nykredit-a-s-purchases-new-position-in-teva-pharmaceutical-industries-ltd-teva-49444cde7f7fa55b 2026-09-05T09:42:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/adverum-biotech-advm-free-cash-flow-2024-92-8m-outflow-down-1-2-48a480bd60f45ef8 2026-09-05T09:09:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-discovery-catapult-backs-uk-biotech-innovators-b7fd54a7eaf805c9 2026-09-05T09:06:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-scientists-made-huge-bets-on-impossible-cancer-treatments-they-re-finally-pa-db7a691a13ee6f25 2026-09-05T09:00:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-given-average-rating-of-moderate-bu-2b9e2a547e63dda0 2026-09-05T08:33:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/symbol-stock-quote-price-and-forecast-eb86857047c09609 2026-09-05T08:16:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-rises-overnight-healthcare-execs-tout-aml-drug-as-game-changer-ahead-o-12a417a1f58a5f3b 2026-09-05T07:59:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/inhibrx-to-present-inbrx-106-phase-2-data-in-head-and-neck-cancer-study-7bc60e333f0cfecf 2026-09-05T07:31:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-extra-year-that-made-all-the-difference-2d795dc0f906e085 2026-09-05T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tarsus-pharmaceuticals-acquires-alkeus-gildeuretinol-for-stargardt-disease-4dd965f22b50d017 2026-09-05T06:41:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/pelacarsen-fails-to-meet-primary-endpoint-in-phase-3-lp-a-trial-0ea1f443261d0062 2026-09-05T06:36:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-small-cap-biotech-posted-impressive-brain-cancer-data-but-there-s-a-catch-4e3e96481ca46f3d 2026-09-05T06:32:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-what-is-behind-the-fresh-attention-95db6bebddecf959 2026-09-05T05:39:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-breast-cancer-drug-etcamah-gets-us-fda-approval-41925e83fc4b1cbb 2026-09-05T04:56:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-3-japanese-ai-healthcare-stocks-to-watch-in-september-2026-75b00280cb33900d 2026-09-05T04:40:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34b 2026-09-05T04:33:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-grand-pharmaceutical-group-sehk-512-is-back-in-the-spotlight-12d7b62e79cc7d2b 2026-09-05T03:53:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747 2026-09-05T03:09:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-and-the-glp-1-story-behind-its-fair-value-gap-08239ff0c5b30182 2026-09-05T02:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-tr-4ff0f635ef6e2a9a 2026-09-05T01:18:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-rare-is-down-40-3-after-angelman-trial-failure-and-ec2e08344eda4d1e 2026-09-05T01:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-endoscopic-versus-shunt-treatment-of-hydrocephalus-in-infants-7bb9776f90b8cebc 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mexican-teachers-cohort-study-genetics-and-cognitive-function-8748cd6c311b8bac 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-consortium-for-advancing-management-and-prevention-of-cancer-in-people-cfcd9f1e3695b9aa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-aina-based-engagement-and-social-epigenomic-pathways-to-metabolic-heal-680bde3ce7adc92c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-modeling-second-hit-somatic-mutations-in-hht-to-uncover-mechanisms-of-39b0d54321e66296 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-regulation-of-proteasome-activity-a44ed2c17835a78e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-bacterial-survival-in-fluctuating-environments-stochastic-switches-rec-015dede062f415e7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/elucidating-the-release-and-permeation-mechanisms-of-emulsion-type-cataplasms-fr-c42dc6128790d2ba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-shelved-pipeline-ai-can-find-strategically-abandoned-medicines-and-bring-the-4f9bf51e7513fec4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/persistence-of-immune-responses-5-years-after-vaccination-with-a-single-dose-of-e754be3d277811a2 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-dvdms-photodynamic-therapy-for-dysphagia-in-advanced-esop-f92c804ed3b86aec 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-antiviral-therapies-in-chronic-hcv-patients-clinical-out-4bcf8aa6f1254c3f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-efficacy-and-safety-of-intraoperative-hyperthermic-intraperitoneal-ch-7f64a205b02b1996 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alianza-terapeutica-y-cambio-clinico-en-psicoterapia-digital-una-revision-sistem-23f9bbee850cb5bf 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/seroprevalence-of-helicobacter-pylori-among-patients-attending-ignatius-ajuru-un-e817d25f76b3529f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-renal-anomalies-associated-with-culture-positive-urinary-tr-6a058814af559638 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcomes-of-paediatric-traumatic-brain-injury-an-experience-b5e4628be31d8910 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcome-of-childhood-cancer-over-2-years-at-a-tertiary-care-0901d6200d429697 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-acute-bacterial-meningitis-prevalence-clinical-profile-and-outcome-lt-b-44fb431196e05a86 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-the-three-component-drug-regimen-glutamyl-tryptophan-bendazole-asc-940b332fe1c13baf 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetic-parameters-of-a-combination-drug-containing-imidazolyl-ethylamid-0baeae1ef1811af1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-chinese-medicine-compound-on-intestinal-bifidobacteria-recovery-and-cd-df2c56cc86dd2216 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/features-of-intestinal-lesions-in-the-clinical-course-of-inflammatory-bowel-dise-970e38ee5edd81b4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unusual-pulmonary-vein-variations-a-new-case-report-and-its-clinical-significanc-4bf10286dc5f4ada 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-proton-pump-inhibitor-therapy-on-micronutrient-and-cognitive-function-62002486099678ba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phospholipid-drug-complex-tagged-snedds-lipid-based-approach-for-oral-bioavailab-c7c8e348c293d485 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-magnesium-supplementation-in-hypomagnesemia-on-wound-healing-in-diabet-3235a2566597306d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-parent-s-knowledge-attitude-and-practice-regarding-self-medication-1a082b786f063c53 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-latent-fingerprints-using-air-dried-plant-extract-powders-an-eco-24b27d64d6b9e5da 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-albumin-and-c-reactive-protein-as-predictors-of-intradialytic-hypotension-527e7083789e3728 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indomethacin-loaded-nano-emulsions-a-promising-topical-platform-for-oral-mucosit-de142850bb89dfba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-a-structured-educational-intervention-on-internalized-shame-and-8a264b80d1242c1f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-for-trocar-site-hernia-a-single-center-6acba75f63e42b8d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-phase-i-cardiac-rehabilitation-exercise-training-combined-with-res-7e11f5cc1ac0f5aa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/obstetric-and-non-obstetric-sources-of-maternal-sepsis-and-their-clinical-outcom-89a82e968531c98d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/membrane-dependent-adsorption-of-lacosamide-in-crrt-implications-for-drug-dosing-11985cfa1e92275b 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/computational-mechanistic-analysis-of-olefin-formation-in-ketyl-radical-mediated-387a0d92a6b60c7c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vitamin-d3-attenuates-delirium-like-cognitive-impairment-in-a-postoperative-mous-eb241ee61b13fa6d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sleep-disorders-and-type-2-diabetes-mellitus-a-narrative-review-of-evolving-rese-730f270c3499e5e1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-nutrition-counseling-on-undernutrition-among-children-aged-6-23-months-663f1c3275a7ca69 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-the-clinic-a-feasibility-trial-of-the-super-skills-for-life-program-for-c-61c73a836a739fb4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/breast-cancer-risk-epigenetic-aging-and-dna-methylation-clocks-dc075747faf8999c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/occurrence-levels-of-alexithymia-in-clinical-nurses-a-systematic-review-and-meta-108c5446f3f8e4c7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-context-feedback-visibility-cfv-framework-mechanisms-of-ai-empowered-clinica-7efd35f46f69cb99 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-insights-into-metastatic-patterns-of-odontogenic-tumors-clinical-charac-eb9af3d399b9272e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-consequences-treatment-status-and-parental-awareness-of-traumatic-denta-fc0a1196aaf37063 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-of-vulvovaginal-atrophy-using-vaginal-dilators-in-addition-to-usual-ca-4242fd54c94d016c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-flow-nasal-cannula-versus-standard-oxygen-therapy-for-adult-acute-hypoxemic-d3e330c8f799849a 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/police-drug-seizures-without-arrest-before-and-during-a-decriminalization-pilot-688876b1023a3c02 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-clinical-prediction-model-for-gastrointestinal-h-1b609f467ec5b699 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/zmynd11-mbtd1-rearranged-acute-myeloid-leukemia-in-chinese-adolescents-and-adult-d8038dd60bc332d8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-recovery-after-intravenous-thrombolysis-for-acute-i-1221e2272189e5a2 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-decision-making-and-management-of-gliomas-in-the-second-trimester-case-9fe4c99be97c0c3e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/routine-clinical-test-markers-with-mri-anatomical-anchoring-for-dysphagia-risk-i-8d698514170983c8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-transcriptomic-profiling-identifies-hub-genes-with-diagnostic-and-clinical-3c85b97a8b7e0394 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autonomic-regulation-as-a-mechanistic-pathway-linking-transcutaneous-auricular-v-8b6316e7240ed992 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/changing-clinical-presentation-of-pediatric-celiac-disease-over-time-632b1d895da2aaca 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-meets-time-assessing-the-impact-of-clinical-decision-support-tools-fo-aae966df0229d21c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stroke-clinical-documentation-education-program-in-australia-and-new-zealand-c16e50de14a9a450 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/telehealth-in-pediatrics-a-quick-review-4397f75451a924a4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-case-worst-case-a-multisite-randomized-trial-of-scenario-planning-for-patie-97c9bff1883fe3f8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/financial-impact-of-a-long-acting-injectable-cabotegravir-rilpivirine-program-a-f2e44332314ebf3f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-scandinavian-perspective-of-the-projected-lifetime-cost-effectiveness-of-rivar-f7f7bd844069977d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ufasomal-nanocarriers-for-enhanced-cardiac-delivery-of-nifedipine-a-novel-strate-afda9338ec3346e3 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-hptlc-method-for-simultaneous-estimation-of-gatifloxacin-and-flur-3592b3a4c663329e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/age-associations-sex-differences-and-interrelationships-of-five-skeletal-maturit-2bd54d31e65ec6bc 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gastrointestinal-tolerance-and-compliance-during-a-2-week-intervention-of-reform-a1263f1c370bc29d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investigating-the-short-term-reliability-of-health-related-physical-fitness-asse-5eeefa5eca21ad72 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burden-of-complex-multimorbidity-and-disparities-in-care-and-support-among-older-657be33be128dfb8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-in-echocardiography-and-point-of-care-ultrasound-applica-d5c8cbce011330d7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-recombinant-bacillus-ligniniphilus-l1-laccase-rice-straw-biocha-3b201a8978622e70 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploiting-binary-eutectic-fatty-acid-systems-for-thermoresponsive-nanocarriers-7f4d2fdc58ed3b61 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-efficacy-of-betamethasone-ciprofloxacin-and-saline-impregnated-nasal-a9a8c4422417da23 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulge-progenitor-cells-a-promising-frontier-in-hair-follicle-regeneration-and-cl-3d7c2672d8da15c8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-conjugates-in-the-treatment-of-esophageal-cancer-d07dfe0cb30e9961 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-supervised-exercise-immediately-after-bariatric-surgery-results-from-7145cbcebd22bb81 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cross-tier-implementation-gaps-in-pharmaceutical-waste-management-evidence-from-1b0cb6f2ef757071 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/institutional-phronesis-theorizing-how-us-primary-care-clinicians-navigate-compe-1dfeb77573914e75 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systemic-evaluation-of-immune-cells-and-cytokines-in-patients-with-different-cli-30b411be4f72f0f0 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/concurrent-emergency-head-and-cervical-spine-ct-utilization-temporal-trends-diag-dc8d9f020852509c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moraxella-species-isolated-from-blood-cultures-in-europe-moraxeu-a-multicentre-s-9dbfe48cf40dc4fa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ibero-american-consensus-on-reactive-arthritis-definition-diagnosis-and-manageme-059966e2abc9b36a 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chloroquine-and-hydroxychloroquine-retinopathy-in-a-cohort-with-rheumatic-diseas-d7f29972f4ddb543 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-practice-guidelines-for-duodenal-cancer-2025-4164950c8ec243b7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-smartphone-based-educational-intervention-on-the-supportive-care-75ad4aa4690acbf1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-survival-of-esophageal-squamous-cell-carcinoma-achieving-pathological-ed2136739cfc6e80 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-post-neurosurgical-intracranial-infections-distinct-clin-1129b9da52f1058f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/video-assisted-versus-conventional-surgical-informed-consent-in-visceral-surgery-5313463edb15ecf5 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-88-meets-72-refining-the-clinical-relevance-of-cesarean-scar-disorder-crite-add3ff9d204cc156 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107ee 2026-09-04T23:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/retatutride-how-the-hunger-for-a-new-weight-loss-drug-is-feeding-an-industry-of-a21a403b35712d2a 2026-09-04T23:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/retatutride-how-the-hunger-for-a-new-weight-loss-drug-is-feeding-an-industry-of-3263ee450ff58f10 2026-09-04T23:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-president-r-d-suma-krishnan-sells-8-98m-in-stock-df91173fa47ede2e 2026-09-04T23:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacars-bc1f4aaad1074d58 2026-09-04T23:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-r-d-head-sells-25-000-shares-under-trading-plan-cb1e83004cab11e9 2026-09-04T23:16:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-ceo-sells-25-000-shares-under-trading-plan-769f72394190993e 2026-09-04T23:15:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-teva-discusses-positive-topline-results-f-1d262411b8d372e2 2026-09-04T23:08:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-microstructure-intelligence-matters-in-pharma-canva-4ef5ef0edcc9f338 2026-09-04T22:57:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-4-2026-7533b9f88b60a135 2026-09-04T22:57:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/budget-for-specialty-pharmaceutical-benefits-set-at-6-73-billion-299e9cedc1dc9a28 2026-09-04T22:25:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-earnings-forward-of-beijing-science-sun-pharmaceutical-co-ltd-class-a-s-f590ad736661f465 2026-09-04T22:18:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-files-for-a-100-million-ipo-30c48b5f6850499b 2026-09-04T22:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-care-down-on-retreat-from-risky-biotech-area-health-care-roundup-8a5b670f583adb85 2026-09-04T21:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-temperature-controlled-shipping-boxes-market-outlook-to-2035-2902f61bf810da37 2026-09-04T21:21:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-et-al-v-food-and-drug-administration-a-case-working-its-way-through-fe-66ad1de31182382d 2026-09-04T21:16:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-experimental-cardiovascular-drug-fails-a-pivotal-study-9ae30b6c2563ebf7 2026-09-04T21:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-a3f827cc018f20b4 2026-09-04T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-rallies-hrt-manufacturers-amid-us-wide-estradiol-patch-shortage-efd1ca9295aa5ff4 2026-09-04T20:37:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-holder-to-sell-25-000-founders-shares-7f15233a6b29e374 2026-09-04T20:35:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-insider-moves-to-sell-2017-shares-in-a-multimillion-dollar-ca5b3b0ebae69cca 2026-09-04T20:34:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pelacarsen-in-pati-867479c87b906007 2026-09-04T20:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-emitio-una-carta-de-advertencia-a-ugal-farmaceutica-s-a-por-incumplimiento-3ee3a16bbcc2f661 2026-09-04T20:25:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-clears-ind-for-acepodia-s-dual-payload-adc-ace723-562cd23a52fb1859 2026-09-04T19:55:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-virtus-lifesci-biotech-products-etf-bbp-affects-rotational-strategy-timing-ba10d3e23ea6d928 2026-09-04T19:54:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-sales-forward-of-ch-biotech-r-d-co-ltd-twse-6534-c184512b86e2c429 2026-09-04T19:31:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-d7df5d6599582fab 2026-09-04T19:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-partners-with-qilu-pharmaceutical-to-commercialize-a-keytruda-biosimilar-i-02acbe0f0bb78c07 2026-09-04T19:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gan-lee-pharmaceuticals-ade7c29f5fb27ce0 2026-09-04T19:22:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-green-light-for-zanvastro-in-alexander-disease-f88683f75405f5fc 2026-09-04T19:04:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-presento-la-experiencia-argentina-en-vigilancia-y-control-post-comercializ-2488a1f0ffb5901f 2026-09-04T19:04:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-793b08ac95d107c2 2026-09-04T19:03:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-f1e282e1506ed3dc 2026-09-04T18:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-price-target-raised-to-48-00-at-ubs-gro-3718e94073907b30 2026-09-04T18:45:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/beone-onc-secured-a-pharmaceutical-tariff-exemption-after-more-than-1b-of-u-s-ma-75b7a23003457f36 2026-09-04T18:44:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/porcine-kidney-xenotransplantation-as-a-bridge-to-allotransplantation-a-first-in-5c486e8a729f25d2 2026-09-04T18:16:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-goldman-sachs-group-issues-pessimistic-forecast-for-ultragenyx-pharmaceutica-679089eff3672c38 2026-09-04T18:15:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/jos-vergeest-appointed-at-symbiosis-bringing-three-decades-of-pharmaceutical-exp-5f4fcc7a587f046f 2026-09-04T18:06:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/rare-brain-disorder-gets-its-first-fda-drug-approval-c9ccac9f39aac17f 2026-09-04T17:52:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-pharma-will-navigate-the-ndc-12-transition-1f1847cc4d566e17 2026-09-04T17:51:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-pauses-autoimmune-car-t-trials-following-three-deaths-a0de109acce01059 2026-09-04T17:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/h-c-wainwright-maintains-legend-biotech-legn-us-with-buy-rating-maintains-target-6ca84d6d182f68e0 2026-09-04T17:42:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/police-response-insufficient-for-crimes-against-pharmacies-report-owners-d78a9e8392e46ad6 2026-09-04T17:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/call-to-expand-shingles-vaccine-following-cardiovascular-research-bf9e54f857af915a 2026-09-04T17:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-zanvastro-pharmexec-ae001a6459d6b4f4 2026-09-04T17:37:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-strikes-again-closes-canteen-at-thane-government-hospital-after-d572cd8cb0d16e22 2026-09-04T17:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-discovery-catapult-backs-two-u-k-biotech-companies-tackling-chronic-di-2a91e1113b88c4ae 2026-09-04T17:28:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-biotech-firm-inks-office-deal-in-south-san-francisco-cb565b9f4316a748 2026-09-04T16:55:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/cockroach-found-in-patient-s-meal-fda-flags-violations-shuts-thane-hospital-cant-ac237dad9aeb2eb7 2026-09-04T16:38:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-advances-new-injectable-obesity-drug-in-key-phase-3-trial-55906840ab9c4121 2026-09-04T16:34:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-s-tilrekimig-eczema-trial-a-fresh-phase-3-catalyst-for-pfe-investors-e00d8772d820793f 2026-09-04T16:34:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/medtronic-executives-to-speak-at-upcoming-investor-conferences-fe0d7b9078a66a84 2026-09-04T16:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-wins-a-big-fda-approval-why-wall-street-is-shrugging-12974b5b8bd07770 2026-09-04T16:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trailing-rivals-abbvie-scores-win-with-dual-acting-myeloma-drug-43b029fb663ef74c 2026-09-04T16:10:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/registration-open-for-sacramento-biotech-summit-at-aggie-square-9524742bf36c6654 2026-09-04T16:05:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/genencell-s-book-value-hits-zero-amid-allegations-kim-seung-won-sought-clinical-5a6dd76f4aaac2ed 2026-09-04T16:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-is-revolutionizing-biotech-can-regulation-keep-up-adcb553923ba9ce2 2026-09-04T15:57:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8 2026-09-04T15:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-pulse-mfn-expansion-goodrx-s-family-plan-csafe-s-reusable-cover-bb893e9003f89293 2026-09-04T15:44:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-upgraded-to-investment-grade-by-s-p-global-ra-5a9fbf7fc25733d9 2026-09-04T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-wall-street-analyst-spotted-the-trial-freeze-then-came-news-of-three-deaths-25accbeac58f1638 2026-09-04T15:33:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/daiichi-unit-american-regent-recalls-3-epinephrine-batches-on-particulate-leakag-9cab5fe17071222c 2026-09-04T15:12:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/va-secures-10b-in-pharmaceutical-price-reductions-so-far-in-fy-2026-e5596cc90a2b64ca 2026-09-04T15:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-attacks-teva-pharmaceutical-company-and-world-health-organization-warehou-01cc1de6ad42dde7 2026-09-04T14:51:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-i-mab-chief-joan-shen-s-neushen-banks-80m-for-3-brain-health-drugs-ac240652b9285082 2026-09-04T14:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-stock-rises-after-naming-raju-willener-as-cfo-by-investing-com-7a40239d54805b10 2026-09-04T14:43:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-digest-expedited-regulatory-pathways-for-biologics-79b10a02d16847cd 2026-09-04T14:43:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-announces-exclusive-partnership-with-qilu-pharmaceutical-for-the-licensing-b2c729fc50676a80 2026-09-04T14:24:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-indonesia-to-the-world-support-beta-pharmacon-s-manufacturing-excellence-wi-c162257ad511f15b 2026-09-04T14:22:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-is-back-with-h1-progress-smoothing-glide-path-through-end-of-year-truist-2ed583a9b16ec59c 2026-09-04T14:11:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-buzz-ions-mist-biib-azn-win-nods-tcrx-nvs-cut-jobs-ovid-vir-data-regn-pas-e786e36eef9e1887 2026-09-04T14:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-appeals-court-to-consider-louisiana-s-arguments-for-banning-telehealth-a-176f77491e2393f9 2026-09-04T14:04:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/q-a-mckesson-s-scott-mooney-on-closing-dscsa-data-exchange-gaps-6c5b4921e97cadab 2026-09-04T14:04:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-april-2025-to-march-2026-bf86900b8a68bc94 2026-09-04T14:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-takes-another-look-at-botanical-drugs-5d3fbf966f8a0faf 2026-09-04T13:51:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/cockroach-found-in-patients-meal-fda-shuts-down-kalwa-hospital-canteen-after-ins-a1552b2176401afc 2026-09-04T13:49:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-biotech-deals-in-august-2026-648c8cfdb1b56b15 2026-09-04T13:21:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/barclays-issues-pessimistic-forecast-for-ultragenyx-pharmaceutical-nasdaq-rare-s-941455bfd6b4c414 2026-09-04T13:16:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/israeli-biotech-firm-picks-indiana-for-north-american-headquarters-00dcd5724fbe51b3 2026-09-04T13:04:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/clearmind-medicine-stock-slides-friday-what-s-happening-e87647c65615b7b7 2026-09-04T12:59:42.000Z weekly 0.7